HopeStage
Back to all studies
CompletedNCT00834834

Dialectical behavior therapy or medication for self-injury and suicide risk

About this title

Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder

Read the official source — NCT00834834
Medication studyAges 18–65United StatesPersonality disorders
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
New YorkSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMarch 2009
Recruitment status
Completed
Enrollment listed in the registry
84
Sponsor
New York State Psychiatric Institute
Sponsor type
Research institute
Study type
Drug
Intervention type
Behavioural, Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00834834
Official title
Show the full official title

Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New York

Registry details
Registry conditions (original wording)

Borderline Personality Disorder; Suicide

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is New York State Psychiatric Institute, a research institute.

Did this study involve medication?

Yes. The study involved medication, including Fluoxetine and Citalopram.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies